Title:Novel Asthma Therapies: A Review
VOLUME: 7 ISSUE: 1
Author(s):Preeti Chopra, Inderpal Randhawa and Terry Chin
Affiliation:2801 Atlantic Avenue, Miller Children’s Hospital, Long Beach, CA 90806, USA.
Keywords:Anti-inflammatory medications, asthma, immunotherapy, inhaled bronchodilators, inhaled corticosteroids,
monoclonal antibody
Abstract:Objective: To describe novel medical therapies in asthma.
Data Sources: A comprehensive Pub Med search was performed and studies published between 2000 and 2008
were reviewed. Updated studies from 2009 to 2011 were also included. A focus was placed on randomized, controlled
studies.
Results: Indacaterol, a once daily inhaled long acting beta 2-agonist (LABA) increased forced expiratory volume in 1 sec
(FEV1) and resulted in prolonged bronchodilation. Ciclesonide, a pro-drug inhaled corticosteroid, has been shown to
increase FEV1 as well as improve morning, evening, and site-measured peak expiratory flow (PEF) with fewer adverse
effects. Fluticasone/formoterol (Flutiform©), a combination inhaled corticosteroid and LABA, showed a reduction in
severe exacerbations requiring hospitalization, increased FEV1, less rescue medication use and higher quality of life
scores. Extra-fine beclomethasone with formoterol also appears promising. Several immunomodulating drugs are on the
horizon. Roflumilast, an oral once-daily PDE-4 inhibitor, improved forced vital capacity (FVC) and reduced the need for
rescue medication. There are encouraging results with mepolizumab and reslizumab, anti-leukin-5 monoclonal antibody
preparations, in a specific subset of asthmatic patients. Other approaches such as anti-interleukin-5 receptor blockage and
anti-interleukin-9 monoclonal antibodies are in the early stages of development. On the other hand, treatment directed
toward anti-tumor necrosis factor in asthmatics has been disappointing.
Conclusions: Novel therapies for asthma continue to evolve. Inhaled corticosteroids continue to be at the forefront of
treatment. However, combination therapies, novel bronchodilators, and PDE4 inhibitors show promise. Many of these
therapies still require further study particularly against the current standards in controller therapy.
